Plain-English translation of NCT06626516 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing , an immune therapy medication, combined with liver-directed therapies for patients with uveal melanoma (a type of eye cancer) that has spread to the liver. The trial has two parts: the first part tests whether combining with a liver procedure called hepatic infusion embolization is safe and effective, and the second part tests this medication combination against alone or against another liver-directed approach. The goal is to find the best way to treat this serious cancer using this new medication.
Uveal melanoma that spreads to the liver is very difficult to treat, and current options are limited. This trial is testing whether this medication, which works by activating the immune system, can work better when combined with treatments that directly target tumors in the liver.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive weekly infusions of the medication , starting with a gradual dose increase over 4 weeks. Depending on which part of the study you enter, you may also receive liver-directed procedures performed by interventional radiologists. The study involves regular clinic visits for treatment and monitoring, blood tests, and imaging scans to check how the cancer is responding. Your participation could last several months, and you will be closely monitored by the research team throughout.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States